Among Asia Pacific pharma companies presenting new clinical data on their oncology pipelines at ASCO, lung and urothelial cancer and antibody-drug conjugates emerge as stand-out themes.
Multiple Asia-based pharma companies are releasing new clinical data on pipeline oncology assets at the American Society of Clinical Oncology meeting in Chicago, and non-small cell lung cancer (NSCLC) and antibody-drug conjugates (ADCs) are emerging as early themes.
The presentations included some significant results in high-need settings and novel targets.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.
Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.
M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.
Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.
